Rapid versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder - RAPID

Study identifier:D1443L00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

RAPID-An Open-label randomized, multicenter phase IIIb study to evaluate the efficacy and tolerability of Quetiapine IR (Immediate Release), over 14 days, in acute schizophrenia/schizoaffective disorder (Rapid versus Conventional Titration)

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

Study drug

Quetiapine IR (Immediate Release)

Sex

All

Actual Enrollment

234

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Jul 2007

Primary Completion Date: -

Study Completion Date: 01 Sept 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

AstraZeneca Clinical Trial Information - Outside US
Download
https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1764&filename=CSR-D1443L00003.pdf
Download
CSR-D1443L00003.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca UK Medical Information Clinical Study Information

01582 836835

Investigators

Principal Investigator

AstraZeneca UK Medical Director

AstraZeneca UK